Zydus Life Science Share Price | Zydus Life Science Stock Screener
ZYDUSLIFE
Pharmaceuticals
Share Price NSE
₹1085.80
▲
6.75 (0.63%)
Share Price BSE
₹1085.95
▲
7.00 (0.65%)
As of May 27, 2026, the Zydus Life Science share price (NSE: ZYDUSLIFE) is ₹1,085.80 on NSE and ₹1,085.95 on BSE, up 0.63% from the previous close, with shares trading between ₹1,074.25 and ₹1,088.90, and a 52-week range of ₹860.60–₹1,085.80.
Check ZYDUSLIFE 52-week chart for the annual price range and momentum.
Use the Zydus Life Science stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Zydus Life Science Market Cap
₹107,963.88 Cr.
ZYDUSLIFE P/E Ratio (TTM)
20.40
Zydus Life Science P/B Ratio
3.86
EPS (TTM)
₹50.09
Dividend Yield
0.10%
Debt to Equity
0.09
ZYDUSLIFE 52 Week High
₹1085.80
Zydus Life Science 52 Week Low
₹860.60
Operating Margin
27.00%
Profit Margin
17.72%
ZYDUSLIFE Revenue (TTM)
₹7,569.00
EBITDA
₹2,139.00
Net Income
₹1,341.00
Total Assets
₹52,407.00
Total Equity
₹27,111.00
Zydus Life Science Share Price Chart
Screen Zydus Life Science share price with an interactive chart. Analyse ZYDUSLIFE price trends and volatility across different timeframes.
Zydus Life Science Company Profile - Fundamental Screener
Screen Zydus Life Science company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for ZYDUSLIFE shares.
Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care,...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Pankaj R Patel
ISIN
INE010B01027
Website
https://www.zyduscadila.com
Zydus Life Science Balance Sheet Screener
Screen ZYDUSLIFE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 52,407 | 37,202 | 29,281 | 25,756 | 27,795 | 23,885 | 23,687 | 23,483 | 18,065 | 15,221 |
| Current Assets | 19,906 | 17,046 | 11,420 | 10,008 | 12,095 | 8,716 | 8,715 | 8,498 | 8,230 | 6,022 |
| Fixed Assets | 20,262 | 13,134 | 12,369 | 11,521 | 12,189 | 12,133 | 12,231 | 12,164 | 6,483 | 5,755 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 7,113 | 1,802 | 1,840 | 541 | 915 | 1,094 | 3,707 | 4,461 | 3,047 | 2,799 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 27,111 | 26,358 | 22,102 | 19,688 | 19,054 | 14,930 | 11,710 | 11,679 | 8,936 | 7,116 |
| Share Capital | 101 | 101 | 101 | 101 | 102 | 102 | 102 | 102 | 102 | 102 |
| Reserves & Surplus | 27,011 | 23,853 | 19,729 | 17,415 | 16,897 | 12,890 | 10,273 | 10,284 | 8,642 | 6,858 |
Zydus Life Science Income Statement Screener - Profit & Revenue Analysis
Screen Zydus Life Science income statement and profit fundamentals.
Analyze ZYDUSLIFE quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Zydus Life Science share price evaluation.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7,569 | 6,892 | 6,147 | 6,622 | 6,371 | 5,181 | 5,182 | 6,110 | 5,526 | 4,403 | 4,313 | 5,089 | 4,890 | 4,199 | 3,993 |
| Expenses | 5,430 | 5,133 | 4,142 | 4,485 | 4,622 | 3,882 | 3,776 | 4,124 | 3,903 | 3,403 | 3,224 | 3,650 | 4,359 | 3,301 | 3,319 |
| EBITDA | 2,139 | 1,759 | 2,005 | 2,137 | 1,749 | 1,299 | 1,407 | 1,986 | 1,623 | 1,000 | 1,089 | 1,439 | 532 | 898 | 673 |
| Operating Profit % | 27.00% | 24.00% | 31.00% | 31.00% | 27.00% | 24.00% | 26.00% | 32.00% | 27.00% | 22.00% | 24.00% | 28.00% | 10.00% | 21.00% | 16.00% |
| Depreciation | 508 | 360 | 302 | 238 | 238 | 229 | 234 | 215 | 205 | 195 | 184 | 180 | 179 | 182 | 182 |
| Interest | 123 | 130 | 101 | 85 | 77 | 32 | 25 | 32 | 35 | 20 | 9 | 18 | 28 | 33 | 35 |
| Profit Before Tax | 1,660 | 1,353 | 1,687 | 1,921 | 1,672 | 1,184 | 1,271 | 1,900 | 1,550 | 947 | 1,006 | 1,328 | 484 | 781 | 648 |
| Tax | 319 | 331 | 449 | 400 | 428 | 158 | 351 | 417 | 304 | 157 | 203 | 195 | 125 | 149 | 122 |
| Net Profit | 1,341 | 1,023 | 1,239 | 1,521 | 1,244 | 1,026 | 920 | 1,483 | 1,246 | 790 | 803 | 1,134 | 358 | 631 | 526 |
| EPS | 12.65 | 10.36 | 12.51 | 14.58 | 11.64 | 10.17 | 9.06 | 14.11 | 11.69 | 7.80 | 7.91 | 10.74 | 2.93 | 6.15 | 5.15 |
Zydus Life Science Cash Flow Screener - Liquidity Fundamentals
Screen ZYDUSLIFE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 6,777 | 3,228 | 2,689 | 2,104 | 3,293 | 2,505 | 1,282 | 919 | 1,312 | 1,894 |
| Investing Activities | -8,377 | -1,492 | 1,178 | 1,137 | -835 | -1,012 | -3,977 | -974 | -2,872 | -860 |
| Financing Activities | 2,014 | -1,810 | -4,400 | -868 | -2,549 | -1,094 | 1,885 | 52 | 2,316 | -935 |
| Net Cash Flow | 414 | -75 | -534 | 2,373 | -91 | 399 | -811 | -3 | 756 | 99 |
Zydus Life Science Shareholding Pattern Screener
See Zydus Life Science shareholding pattern with promoter, FII, and DII holdings.
Check Zydus Life Science promoter holding and ownership changes for ZYDUSLIFE on TickJournal.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 75.00% | 75.00% | 74.99% | 74.99% | 74.99% | 74.98% | 74.98% | 74.98% |
| FII Holding | 6.95% | 7.06% | 7.34% | 7.13% | 7.32% | 7.53% | 7.52% | 5.59% |
| DII Holding | 11.20% | 11.09% | 10.86% | 11.13% | 11.01% | 10.65% | 10.65% | 12.64% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 5.54% | 5.54% | 5.49% | 5.46% | 5.41% | 5.47% | 5.48% | 5.37% |
| Other Holding | 1.32% | 1.31% | 1.32% | 1.28% | 1.28% | 1.36% | 1.37% | 1.43% |
| Shareholder Count | 418,314 | 403,266 | 396,105 | 386,127 | 371,619 | 365,356 | 370,863 | 336,309 |
Zydus Life Science Share Dividend Screener - Share Yield Analysis
Check Zydus Life Science dividend history with payout and yield data.
View Zydus Life Science dividend details including ex-dates and amounts for ZYDUSLIFE stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹11.00 | 1.26% |
| 2024-March | ₹3.00 | 0.34% |
| 2023-March | ₹6.00 | 0.60% |
| 2022-March | ₹2.50 | 0.51% |
| 2021-March | ₹3.50 | 1.00% |
| 2020-March | ₹3.50 | 0.79% |
| 2019-March | ₹3.50 | 1.31% |
| 2018-March | ₹3.50 | 1.01% |
| 2017-March | ₹3.20 | 0.85% |
Zydus Life Science Stock Index Membership
See which indices include Zydus Life Science stock.
Check ZYDUSLIFE index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE 200 EQUAL WEIGHT
BSE INDEX BSE HC
BSE INDEX BSE200
BSE INDEX BSE500
BSE INDEX BSEDSI
BSE INDEX LMI250
BSE INDEX LRGCAP
BSE INDEX MID150
BSE INDEX MSL400
NIFTY 100
NIFTY 200
NIFTY 500
NIFTY ALPHA QUALITY LOW-VOLATILITY 30
NIFTY ALPHA QUALITY VALUE LOW VOLATILITY 30
NIFTY ALPHALOWVOL
NIFTY HEALTHCARE
NIFTY INDIA MFG
NIFTY LARGEMID250
NIFTY NEXT 50
NIFTY PHARMA
NIFTY TOTAL MKT
NIFTY100 ENHANCED ESG
NIFTY100 EQL WGT
NIFTY100 ESG
NIFTY100 QUALTY30
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 SHARIAH
Zydus Life Science Market Events Screener - Corporate Actions
Get Zydus Life Science corporate actions including splits, bonuses, and buybacks.
Check Zydus Life Science stock events that may affect ZYDUSLIFE share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-11 | 2026-08-11 | Annual General Meeting | NA | 4.83% |
| 2026-07-24 | 2026-07-24 | Dividend | ₹ 1.00 /share | 4.83% |
| 2026-05-29 | 2026-05-29 | Buyback | 1150 | 0.00% |
| 2026-05-19 | 2026-05-19 | Quarterly Result Announcement | NA | 5.42% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 0.67% |
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -2.96% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -1.47% |
| 2025-08-12 | 2025-08-12 | Annual General Meeting | NA | 4.84% |
| 2025-07-25 | 2025-07-25 | Dividend | ₹ 11.00 /share | 7.57% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 4.31% |
| 2025-02-05 | 2025-02-05 | Quarterly Result Announcement | NA | -2.16% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | -3.36% |
| 2024-08-09 | 2024-08-09 | Annual General Meeting | NA | 26.80% |
| 2024-07-26 | 2024-07-26 | Dividend | ₹ 3.00 /share | 19.50% |
| 2024-02-23 | 2024-02-29 | Buyback | 1005 | -2.20% |
Zydus Life Science Competitors Screener - Peer Comparison
Screen ZYDUSLIFE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,622 | 40.42 | 58,220 | 6.38% | 11,565 | 54.03 |
| Divis Laboratories | 179,364 | 73.73 | 10,560 | 8.73% | 2,520 | 57.30 |
| Torrent Pharmaceuticals | 154,758 | 66.80 | 13,753 | 19.18% | 2,028 | 66.36 |
| Cipla | 114,212 | 29.26 | 27,712 | -2.46% | 3,783 | 64.19 |
| Dr Reddys Laboratories | 111,124 | 26.24 | 33,593 | -0.44% | 3,998 | 57.44 |
| Zydus Life Science | 107,964 | 20.40 | 26,720 | 13.65% | 5,242 | 73.90 |
| Lupin | 104,535 | 19.46 | 27,488 | 19.98% | 5,345 | 48.15 |
| Mankind Pharma | 101,447 | 52.84 | 14,278 | 12.03% | 1,750 | 59.66 |
| Aurobindo Pharma | 84,483 | 24.29 | 33,385 | 3.21% | 3,376 | 51.11 |
| Laurus Labs | 73,221 | 81.46 | 6,813 | 21.03% | 884 | 78.36 |
Zydus Life Science Company Announcements - News Screener
Screen ZYDUSLIFE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-27 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-25 | Corporate Action-Updates on Buy back | - |
| 2026-05-25 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-24 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-24 | Announcement under Regulation 30 (LODR)-Updates on Acquisition | - |
| 2026-05-24 | Announcement under Regulation 30 (LODR)-Updates on Acquisition | - |
| 2026-05-24 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-23 | Corporate Action-Updates on Buy back | - |
| 2026-05-23 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-05-23 | Corporate Action-Updates on Buy back | - |
| 2026-05-23 | General Update On Buyback | - |
| 2026-05-23 | Record Date For Buy Back | - |
| 2026-05-23 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-23 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-05-23 | Record Date For Dividend July 24 2026 | - |
| 2026-05-23 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-05-23 | Corporate Action-Buy back | - |
| 2026-05-23 | Corporate Action-Board approves Dividend | - |
| 2026-05-23 | Board Meeting Outcome for Audited Financial Results For The Quarter / Year Ended On March 31 2026 | - |
| 2026-05-23 | Audited Financial Results For The Quarter / Year Ended On March 31 2026 | - |